Winter Storm Update: MSK is preparing for the coming storm. Read more

A Phase I Study of LY3321367 with or without LY3300054 Immunotherapy in Patients with Advanced Solid Tumors

Full Title

A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination with LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors


LY3321367 and LY3300054 are both immunotherapy drugs that boost the power of the immune system to find and kill cancer cells. They do so by blocking proteins that help cancer cells escape detection by the immune system. LY3321367 inhibits the TIM-3 protein, while LY3300054 blocks the PD-L1 protein.

In this study, researchers are assessing the safety and best dose of LY3321367 when used alone and in combination with LY3300054 in patients with advanced solid tumors that have continued to grow despite prior therapy. Patients will receive just LY3321367 or both drugs. They are both given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced or metastatic solid tumor that has continued to grow despite prior treatment.
  • Previous immunotherapy, such as nivolumab or pembrolizumab, is permitted.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. James Harding at 646-734-9309.